Journal for Pharmaceutical Regulatory Affairs
May
18
The Federal Emergency Management Agency intends to prepare an Environmental Impact Statement evaluating the impacts on the quality of the human environment of the National Flood Insurance Program as it is currently implemented and of potential future changes to the Program
written by
Journal for Pharmaceutical Regulatory Affairs
Journal for Pharmaceutical Regulatory Affairs
May
18
The NPRA is backed by patients, caregivers, businesses and a range of other supporters. Collectively, the coalition is working to broaden awareness, reach legislators in a targeted manner, and help mobilize patients and caregivers who are affected by current and proposed medical marijuana laws. A key objective of the coalition is a push for definitive regulation in terms of standardization — ranging from safety and storage needs, document management requirements, privacy, and overall industry standards and procedures.
written by
Journal for Pharmaceutical Regulatory Affairs
Journal for Pharmaceutical Regulatory Affairs
May
14
The U.S. regulatory environment strongly impacts innovation and the development of new drugs and biologics. With this in mind, the Achieving Regulatory Approval and Compliance educational track at the 2012 BIO International Convention will tackle the most pressing regulatory issues facing the industry, specifically the reauthorization of the Prescription Drug User Fee Act (PDUFA V), implementation of the new biosimilars pathway, and efforts to modernize and expedite drug development. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA.
written by
Journal for Pharmaceutical Regulatory Affairs